NasdaqGS:BIIBBiotechs
Why Biogen (BIIB) Is Up 5.8% After Q2 Revenue Beat And Raised 2026 Guidance - And What's Next
Biogen Inc. has reported its second-quarter 2026 results, with revenue rising to US$2.74 billion from US$2.65 billion a year earlier while net income dropped sharply to US$97.5 million and diluted EPS from continuing operations fell to US$0.66 from US$4.33.
Behind the headline revenue beat and upgraded full-year guidance, Biogen’s expanding growth portfolio and Apellis acquisition are increasingly offsetting pressure on legacy multiple sclerosis therapies.
We’ll now examine how Biogen’s...